Travere Therapeutics and Everest Medicines announced an exclusive license for civorebrutinib outside China and select Asia, with $112.5 million upfront and potential milestones up to about $1.03 billion. The collaboration expands Travere’s rare kidney disease portfolio and could position civorebrutinib as a best-in-class therapy across PMN, FSGS, and MCD, supported by prior Phase 1/2 signals. The deal creates near-term cash value and long-run pipeline optionality should development progress and regulatory approvals succeed.
Travere Therapeutics received FDA approval for the expanded use of its drug targeting a rare kidney disorder. This expansion could lead to increased market presence and revenue, potentially enhancing Travere's financial outlook in the coming quarters.
FDA approved updated REMS labeling for TVTX's Filspari. Liver function monitoring frequency reduced to every three months. Embryo-fetal toxicity monitoring requirement removed based on safety data. Supplemental FDA application for Filspari in FSGS under review. Filspari could be the first approved medicine for FSGS.
- Travere Therapeutics had a 27.4% revenue decline and EPS of -$1.76. - Revenue of $41.37 million was below the Zacks Consensus Estimate by -2.70%. - Key metrics like Tiopronin products revenue saw a -4.8% change year over year. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- Travere Therapeutics reported a quarterly loss of $1.76 per share, missing estimates. - Revenues for the quarter ended March 2024 were $41.37 million, missing estimates by 2.70%. - Travere's stock has lost about 30.4% since the beginning of the year. - Estimate revisions trend for Travere is unfavorable, resulting in a Zacks Rank #5 (Strong Sell). - Medical - Biomedical and Genetics industry is in the top 32% of Zacks industries. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Research Analysis
